NYSE ARCA | ETF
The fund, under normal circumstances, invests at least 80% of its assets in the securities that comprise the index or investments with economic characteristics similar to the securities included in the index.
The index provides exposure to the performance of companies, publicly listed in the United States, Canada and Europe, that are leading the development and application of messenger RNA ("mRNA") technology.
The fund is non-diversified.
Top 10 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc | Healthcare | Biotechnology | 8.22% |
| BGNE | BeiGene Ltd | Healthcare | Biotechnology | 6.80% |
| ALNY | Alnylam Pharmaceuticals Inc | Healthcare | Biotechnology | 6.64% |
| MRNA | Moderna Inc | Healthcare | Biotechnology | 6.26% |
| BNTX | BioNTech SE | Healthcare | Biotechnology | 6.26% |
| PTCT | PTC Therapeutics Inc | Healthcare | Biotechnology | 6.14% |
| ARCT | Arcturus Therapeutics Holdings Inc | Healthcare | Biotechnology | 6.13% |
| SRPT | Sarepta Therapeutics Inc | Healthcare | Biotechnology | 6.12% |
| MRVI | Maravai Lifesciences Holdings Inc | Healthcare | Biotechnology | 5.06% |
| NTLA | Intellia Therapeutics Inc | Healthcare | Biotechnology | 4.67% |